The transformation of normal melanocytes into melanoma

Summary

This project investigates the role of the oncogenes Ras and Braf and the tumour suppressors p16INK4a, p14ARF, p53 and PTEN in the malignant transformation of melanocytes.

Supervisor(s)

Professor Richard Kefford

Research Location

Westmead - Westmead Institute for Medical Research

Program Type

Masters/PHD

Synopsis

The cell cycle research group investigates the biomolecular mechanisms of melanomagenesis. Our main focus is to investigate the function of the tumour suppressor products of the INK4a/ARF locus, which displays germline mutations in 39% of melanoma-prone families. This locus encodes the melanoma associated tumour suppressor proteins, p16INK4a and p14ARF. Thus, many melanoma-prone individuals express both wild type and mutant forms of these proteins, and the impact of this heterozygous state is being investigated. In particular, we are establishing critical melanoma models to define whether accumulation of mutant proteins alters the function of their wild type counterparts. Both the p16INK4a and p14ARF proteins inhibit cell proliferation and induce of a tumour suppressive “senescent” state, that potentially protects melanocytes from oncogene induced transformation . The aberrant activation of the N-RAS and BRAF oncogenes in melanocytes can trigger a growth arrest response, that is bypassed by additional genetic alterations. We are currently investigating the mechanisms responsible for this growth arrest response, which is clearly critical in protecting against melanoma formation in sun-exposed skin. Our research efforts into the biomolecular pathways that link p16INK4a and p14ARF to melanoma are aimed towards finding biomolecular targets for melanoma therapy in the future. To date such therapy is completely bereft of successful strategies once the disease has reached the metastatic state.

Additional Information

Our research involves a variety of molecular and tissue culture techniques such as cloning of genes into mammalian expression vectors, transfection, Western analysis, immunocyto-staining, culture of tumour cell lines and primary cells (2D and 3D culture), transfection, lentiviral gene transfer, real time PCR, FACS analysis and more. Current projects are: Molecular determinants of escape from BRAF-induced human melanocyte senescence in the genesis and targeted control of melanoma.

  • This project involves lentiviral transfer of oncogenes or lentiviral silencing to clarify whether p16INK4a and p14ARF protect from melanoma genesis.
The impact of mutant p16INK4a on wild type p16INK4a function and melanoma proliferation
  • This project will investigate a possible dominant negative effect of mutant p16INK4a on the wild type protein.
Mechanism of p14ARF induced apoptosis
  • This project clarified that while p14ARF alone does not cause apoptosis, it leads to increased cell death in combination with certain cytotoxic drugs.
The melanoma-associated ARF tumour suppressor modulates cell proliferation and apoptosis via target protein sumoylation
  • We have recently identified a novel sumoylation function through which ARF may exert its cell cycle inhibitory and tumour suppressor functions. This function is being investigated and new p14ARF sumoylation targets are being identified.
The tumour suppressor p16INK4a binds the chromatin remodeling factor BRG1 to regulate the cell cycle and senescence
  • We have recently identified a novel binding partner of p16INK4a and our data show that it co-operates with p16INK4a in cell cycle regulation.

Want to find out more?

Contact us to find out what’s involved in applying for a PhD. Domestic students and International students

Contact Research Expert to find out more about participating in this opportunity.

Browse for other opportunities within the Westmead - Westmead Institute for Medical Research .

Keywords

Cutaneous melanoma, melanoma, p16INK4a, p14ARF, p53, PTEN, N-Ras, Braf, cell cycle, senescence, Cell biology, Genes in biology & medicine

Opportunity ID

The opportunity ID for this research opportunity is: 219